The Conversation (0)
Canopy Growth announced the acquisition of a German-based cannabis researcher for cannabinoid medical therapies.
Canopy Growth (NYSE:CGC,TSX:WEED) announced the acquisition of a German-based cannabis researcher for cannabinoid medical therapies.
As quoted in the press release:
Canopy Growth is pleased to announce that it has acquired German-based, Bionorica SE-founded C3 Cannabinoid Compound Company (C3) in a transformative deal that will see established single cannabinoid medicines brought together with the world’s leading full-spectrum medical cannabis offering.
The all cash-acquisition for €225.9 million (CDN $342.9 million) furthers Canopy Growth’s expansion into European markets with prescription medicines and gives the Company immediate access to a wealth of knowledge and intellectual property that C3 has developed in its nearly 20 years of research and development into synthetic and natural cannabis medical products.
“What this boils down to is greater choice,” said Bruce Linton, Chairman & Co-CEO, Canopy Growth. “This acquisition will allow us to offer more options to physicians across Europe, accelerate our commercial sales and increase our economic footprint on the continent, and drive forward new innovations. Our goal is to build on C3‘s extraordinary reputation and decades of success as we move to an innovative continuum of medical cannabis therapies that will enable physicians globally to better treat their patients.”